Political, economic, or social advocacy are vehicles for altering existing structural systems, changing behavior on a large scale, and promoting a new status quo. High-capacity philanthropists are uniquely positioned to leverage their resources in the interests of generating social impact and systemic change.
Whether or not you decide to engage in advocacy should come down to your personal goals as a philanthropist. A few basic questions will guide you.
Do the changes I want to see in the world rely on more than philanthropy?
If you aim to address systemic problems that require public engagement or regulatory changes, then advocacy might be an appropriate vehicle to achieve your charitable priorities. Similarly, if you are passionate about amplifying the voices of vulnerable groups in society, advocacy is an excellent way to advance your cause.
How can I engage in advocacy?
Advocacy is often considered synonymous with lobbying, but its definition is much broader.It is any action that promotes a point of view or aims to influence others. The full spectrum of advocacy includes a wide variety of activities, including:
Grassroots mobilization
Public education campaigns
Publicity campaigning
Coalition building
Conducting research
Political lobbying
What do I need to be aware of before I start?
Your chosen philanthropic vehicle will determine the extent of your advocacy activities. For example, an LLC has more flexibility than a private foundation. Acting as an individual or via an LLC allows you to engage in direct lobbying or to make personal gifts to 501(c)(3) charitable nonprofits or 501(c)(4) social welfare organizations to promote a chosen cause. It’s important to remember that some of these tactics will not be tax deductible, including any contributions to an LLC or 501(c)(4) social welfare organization. Nonetheless, these groups have the potential to influence your objectives for social or environmental progress. We recommend consulting with your legal counsel to ensure compliance when engaging in advocacy activities.
Today, the Milken Institute announced the spin-off of Breakthrough Discoveries for thriving with Bipolar Disorder (BD²) to continue its long-term growth in accelerating scientific understanding of bipolar disorder.
Imagine living with a disease so mysterious that few people have heard of it—yet it shapes every part of your daily life. For millions of people living with rare or poorly understood health conditions, their (often devastating) symptoms are...
Associate Director, Science Philanthropy Accelerator for Research and Collaboration (SPARC) team, Milken Institute Strategic Philanthropy
Quinton Banks,PhD, is an associate director on the Science Philanthropy Accelerator for Research and Collaboration (SPARC) team at Milken Institute Strategic Philanthropy. His extensive scientific background includes research into chronic pain, taste perception, and muscle physiology.
February 20, 2026 (Washington, DC)—The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann Theodore Foundation (ATF), has launched a new funding program to support a future...
The Ann Theodore Foundation (ATF) is launching a new funding program to support the study of repurposed mechanistic target of rapamycin (mTOR) inhibitors as treatments for cutaneous sarcoidosis. This program will be executed in partnership...
As underscored by recent conversations at Davos highlighting Africa’s growing role as a key player in the global economy, 2026 is set to be a critical year for investment across the continent.
Schizophrenia is a serious, chronic brain disorder affecting about 24 million people worldwide. Individuals with schizophrenia experience a variety of symptoms—most notably psychosis—and face significant challenges accessing the care they...
The Milken Institute is a nonprofit, nonpartisan think tank focused on accelerating measurable progress on the path to a meaningful life. With a focus on financial, physical, mental, and environmental health, we bring together the best...
While philanthropic investment in any area of biomedical research or health care is worthwhile when done strategically, rare diseases are especially compelling targets for philanthropic dollars.
Associate Director, Science Philanthropy Accelerator for Research and Collaboration (SPARC) team, Milken Institute Strategic Philanthropy
Elizabeth Burke, PhD, is an associate director on the Science Philanthropy Accelerator for Research and Collaboration (SPARC) team at Milken Institute Strategic Philanthropy. Her expertise lies in rare disease research, including neurodevelopmental and neurodegenerative disorders, strategic planning, project management, and promoting collaboration between clinical and scientific teams.
Across Southeast Asia, companies are embedding social impact goals into their core strategies to address pressing national challenges, ushering in a new era of corporate philanthropy for the region. Developments in the region offer new...
Across Southeast Asia, companies are embedding social impact goals into their core strategies to address pressing national challenges, ushering in a new era of corporate philanthropy for the region...